We’re researching a study medicine for transformed small cell lung cancer (T-SCLC)

All participants will receive the study medicine – there is no placebo or comparator group in this clinical trial. The study medicine will be given alone and in combination with chemotherapy. This clinical trial will help researchers learn if the study medicine combined with chemotherapy or the study medicine alone can be used as a safe treatment for people with T-SCLC. 

If you choose to take part in this clinical trial, you could help us continue to make progress in T-SCLC.

Who may participate

You may be eligible to participate in this clinical trial if you are aged 18 or older and: 

  • have been diagnosed with T-SCLC 
  • have not previously received any anti-cancer treatment for T-SCLC (some prior chemotherapy may be allowed) 
  • have a prior diagnosis of EGFR-mutated non-small cell lung cancer and have received treatment with a targeted therapy (tyrosine-kinase inhibitor) 

This is not a complete list of eligibility criteria for this clinical trial. The study doctor will review all eligibility criteria with you.

Condition

T-SCLC

Age

18+ years

Sex

Male or Female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this clinical trial is a good fit for you and you decide to participate, you will receive the study medicine in combination with chemotherapy. You will initially receive the study medicine with chemotherapy, then the study medicine alone until your cancer worsens, you experience bad side effects, or you or the study doctor decides you should stop. 

You will have regular study visits while receiving the study treatment. Most study visits are expected to last approximately 3 to 5 hours and will consist of different types of tests, procedures, and assessments. 

All participants will have an in-person follow-up visit or phone call every 12 weeks.

Length of study treatment

About 7 months or until the cancer worsens, or you or the study doctor decides to stop

Follow up

In-person visit or phone call every 12 weeks

About the study medicine

Mature couple looking out the window – Pfizer Clinical Trials
Mature couple looking out the window – Pfizer Clinical Trials

About the study medicine

The study medicine is a bispecific antibody designed to target two different proteins, PD-1 and VEGF, at the same time. These proteins can play a role in how the cancer grows and how the immune system responds to it. It is thought that by binding (or connecting) to these two proteins, the study medicine may help the immune system find and attack the cancer cells while also potentially slowing down tumor growth, which may be more effective for treating T-SCLC. 

The study medicine will be given as an intravenous (IV) infusion, meaning directly into the bloodstream through a small tube inserted into a vein.

Potential risks and benefits of taking part in the clinical trial

People who take part in clinical studies are key to advancing medical research. By taking part in this clinical trial, you will be helping to advance research which may help yourself and others with T-SCLC in the future. 

This clinical trial offers the opportunity to explore how a potential study medicine may work when combined with standard chemotherapy, for people with T-SCLC. 

Participant safety is the top priority of this clinical trial. It is possible your condition or health may improve, worsen, or stay the same. Your study doctor will discuss all the possible risks and benefits of participating with you if you qualify and choose to enroll. 

In addition: 

  • The study team will monitor your health closely during the clinical trial 
  • The study treatment and any study-related procedures will be provided at no cost 
  • Travel support may also be available 
  • You will help advance research for the future of T-SCLC treatments

Potential risks and benefits of taking part in the clinical trial

Mature man on street – Pfizer Clinical Trials
Mature man on street – Pfizer Clinical Trials

Frequently asked questions

Why is this research important?

The Symbiotic-Lung-14 clinical trial will help researchers learn if the study medicine combined with chemotherapy or the study medicine alone can be used as a safe treatment for people with T-SCLC. There are currently no approved treatments, and standard chemotherapy alone may not work for long. There is an urgent need to develop potential therapies that can improve the long-term prognosis for people with T-SCLC.

Is this helpful?
Is there a cost to participate in this clinical trial?

The study treatment and any study-related procedures are generally covered at no cost. You may be reimbursed (paid back) for reasonable expenses that you and your caregiver have as a result of taking part in this study. This may include parking, meals, or other travel-related expenses. Please speak with the study doctor if you have any questions about costs resulting from being in this study.

Is this helpful?
What are biomarkers and why do your samples matter?

As part of this study, we will analyze your blood samples and a small portion of your tissue sample to examine various biological indicators known as biomarkers. These biomarkers will help us understand how the study drug interacts with your body and what factors may influence its effectiveness. By studying these markers, we aim to identify which patients are most likely to benefit from this treatment in the future.

Is this helpful?
Learn more
Discover locations for this study
Discover

Continue exploring

how clinical trials work

How clinical trials work

saftey shield

Protecting your safety & privacy

clipboard

Steps to join a clinical trial

FAQ

FAQs